Mycosis Fungoides

Watchlist

(log in to enable)

Retrieved

2022-04-26

Source

Gard

Trials

—

Genes

TNFRSF1B, CTLA4, CD28, TNFRSF8, TRBV20OR9-2, TP53, IL2, MIR155, CDKN2A, DPP4, STAT3, IFNG, TRBV16, TRBV7-9, PTEN, TRBC1, TRB, IL4, FOXP3, IL17A, TSPYL2, NAV3, TOX, HLA-DQB1, PIK3CA, AKT1, TNF, IL10, CCR4, IL32, IL6, TARP, ALK, STAT4, FAS, CD40LG, NCAM1, CCR10, CDKN2B, PIK3CB, TRG, PIK3CD, PIK3CG, TRGC1, VEGFA, IL15, IL16, IRF4, IL7, PTGS2, JUNB, KIR3DL2, PTPRC, CADM1, SMUG1, CCL27, NOTCH1, CCL21, VEGFC, MAPK1, CXCL11, LINC02605, CXCR3, HLA-DRB1, MIR223, HLA-B, MIR93, B2M, MALAT1, MIR21, SOCS1, CFLAR, SOCS3, USP14, USP2, MIR34A, RBM45, MIR17, IL31, TRIP13, DEFB103A, PLA2G4D, GRAP2, TCL1B, MIR122, MIR126, DEFB103B, TP63, AHSA1, MTCO2P12, LUNAR1, ERVK-11, ERVK-22, WNT1, YY1, ERVK-12, ERVK-2, DEFB4B, HBD, ZNF217, CDKN2B-AS1, MIR326, CXCR4, AIMP2, NR4A3, TCL1A, TCIRG1, PDPN, IL17F, UVRAG, CD274, ERVW-1, RNF34, RAPH1, BCL11B, NFKBIZ, MIB1, TLR7, IL23A, ATF7IP, INTS2, GDE1, DUSP22, TLR9, DIABLO, SOX18, KRT20, RHOF, PPP1R2C, TRBJ2-1, HM13, TRBJ2-7, GNG8, CKAP4, IL33, ACSBG1, PWWP3A, HAVCR2, KLK5, PART1, RNF19A, DNM3, POLDIP2, INTS1, SGSM3, DLL1, QTRT1, SHARPIN, TRBV5-7, VDR, ACVRL1, UCHL1, GZMB, FGFR1, FKBP4, FKBP5, FLT4, MTOR, FUT4, GATA3, GNAO1, GNAS, GRN, HDAC2, TNFRSF4, HELLS, HHEX, HLA-A, HLA-DPB1, HLA-DQB2, HLA-G, HNRNPK, HRAS, ICAM3, IFNA1, FGF3, FGF2, EPHB2, E2F1, ANPEP, ARG1, CCND1, BCL2, BCL7A, BCR, BRCA2, CASP8, CBL, CD7, MS4A1, CD40, CD44, CDO1, CREB1, CRK, MAPK14, CTNNB1, CTSB, DEFB1, DEFB4A, IFNA13, IL1B, IL5, NOS2, PAK1, PDCD1, PKM, PPP1R1A, PSMB6, RAF1, RPE65, SATB1, PARP1, CCL5, CCL20, CXCL12, SELL, SELPLG, SLPI, SS18, MAP3K7, TGFB1, TLR2, TLR4, NR2C2, NPM1, NOS1, IL9, NKG7, IL13, ITGAM, ITGB2, JAK2, JAK3, JUND, KIT, KRT1, LGALS1, LPP, LTA, MEF2C, MKI67, MLH1, MMP1, MMP2, MMP9, MTAP, COX2, MYBL2, MYCL, SCT

Drugs

A-dmDT390-bisFv(UCHT1), Adenovirus-Interferon gamma - coding DNA sequence, Alisertib

A-dmDT390-bisFv(UCHT1), Adenovirus-Interferon gamma - coding DNA sequence, Alisertib, Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus, Belinostat ( BELEODAQ ), Brentuximab vedotin ( ADCETRIS ), Chlormethine ( Ledaga ), Darinaparsin, Denileukin diftitox, Fenretinide, Forodesine hydrochloride, Human monoclonal antibody against CD4, Humanised IgG1 monoclonal antibody against human KIR3DL2, Iodine (131I) tositumomab, Meclorethamine ( VALCHLOR ), Miltefosine ( IMPAVIDO ), Mogamulizumab ( POTELIGEO ), N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin)benzamide, Naloxone hydrochloride dihydrate, Panobinostat ( FARYDAK ), Pralatrexate ( FOLOTYN ), Recombinant anti-CD3-bi-single-chain-Fv-diphtheria toxin fusion protein, Resiquimod, Romidepsin ( ISTODAX ), Siplizumab, Suberolylanilide hydroxamic acid, Synthetic hypericin, Vorinostat ( ZOLINZA ), Zanolimumab, haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate, oligonucleotide inhibitor of microRNA miR-155-5p

Interested in hearing about new therapies?

Mycosis fungoides is a disease in which T-cell lymphocytes (a type of white blood cell) become malignant (cancerous) and affect the skin. This condition is one of the most common types of T-cell lymphoma. Mycosis fungoides is characterized by a scaly, red rash that develops on the skin, particularly on areas that are not usually exposed to the sun. The rash may last for months or years without causing any symptoms. Over time, a thin, reddened, eczema-like rash may develop, followed by thickened, red patches of skin. Finally, tumors form which may develop into ulcers and become infected. Mycosis fungoides is difficult to cure. Treatment is usually palliative, with the intention of relieving symptoms and improving the quality of life.